- In May 2026, Doximity reported higher quarterly and full-year revenue but lower net income, issued more cautious revenue guidance amid rising AI-related costs, filed a US$39.16 million shelf registration for 2,000,000 Class A shares tied to an ESOP, and announced new President and CFO appointments alongside an Aledade AI-integration partnership.
- An emerging securities investigation and management’s focus on AI tools such as Scribe and Ask highlight how rising compute expenses and regulatory scrutiny are reshaping Doximity’s cost structure and risk profile.
- We’ll now examine how the combination of subdued revenue guidance and AI-related cost pressures may alter Doximity’s investment narrative.
Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.
Doximity Investment Narrative Recap
To own Doximity today, you need to believe its physician network and AI tools can deepen its role in clinical workflows, even as profitability comes under pressure. The key near term catalyst is whether AI products like Scribe and Ask drive higher engagement and upsell, while the biggest current risk is that rising AI compute costs and softer revenue guidance compress earnings. The latest results and guidance appear directly relevant to both that catalyst and that risk.
Among the recent announcements, the Aledade integration looks most relevant. Embedding Scribe and Ask into Aledade Assist puts Doximity’s AI suite in front of value based primary care clinicians, aligning with the thesis that workflow tools can increase stickiness and potential monetization. At the same time, this type of AI deployment is exactly what is contributing to higher compute expenses, which investors now need to weigh more carefully against the long term opportunity.
Yet beneath the promise of new AI workflows, investors should also be aware that rising compute costs and fresh securities scrutiny could...
Read the full narrative on Doximity (it's free!)
Doximity's narrative projects $782.1 million revenue and $249.4 million earnings by 2029.
Uncover how Doximity's forecasts yield a $37.77 fair value, a 89% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were expecting revenue near US$820,000,000 and earnings of about US$262,500,000 by 2029, but the latest AI driven cost pressures and competition risks could challenge those assumptions and show just how differently you and other investors might view Doximity’s future.
Explore 4 other fair value estimates on Doximity - why the stock might be worth 10% less than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Doximity research is our analysis highlighting 2 key rewards that could impact your investment decision.
- Our free Doximity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Doximity's overall financial health at a glance.
Ready For A Different Approach?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
- We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Find 48 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com